KHKoichi Hirabayashi

Koichi Hirabayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koichi Hirabayashi has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bispecific Ligand‐Based EphB4 CAR‐T Cells Generated Using Ephrin‐B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma

    by Hirotaka Kumeda, Koichi Hirabayashi, Shuji Mishima, Kotaro Morita, Yu Furui, Marina Fujioka, Tomoyuki Nakajima, Miyuki Tanaka, Yoshinori Sato, Takeshi Uehara, et al.

    Chimeric antigen receptor (CAR)‐T cells generated using ephrin‐B2, the natural ligand for ephrin type‐B receptor 4 (EphB4), have demonstrated antitumor activity; however, their efficacy remains unvalidated. Therefore, we evaluated the dual‐targeting antitumor ability of these cells and confirmed their efficacy against lung adenocarcinoma. First, we evaluated EphB4 and EphA2 expression in samples from 74 patients with lung adenocarcinoma using immunohistochemistry. Next, EphB4 CAR‐T cells were generated via piggyBac ‐mediated gene transfer, and their phenotype was evaluated. Subsequently, we conducted an antigen stimulation assay to assess the bispecificity of the EphB4 CAR‐T cells. Finally, the antitumor effects of EphB4 CAR‐T cells on lung adenocarcinoma cell lines were assessed. EphB4 and EphA2 positivity in lung adenocarcinoma samples was 93% and 100%, respectively. EphB4 CAR‐T cells were successfully generated with high CAR positivity and a high proportion of naïve/stem cell memory‐like T cells. In the antigen stimulation assay, the cells responded in an antigen‐specific manner after stimulation with both EphB4 and EphA2 proteins. In the co‐culture experiment, EphB4 CAR‐T cells significantly suppressed the growth of all four lung adenocarcinoma cell lines compared to mock‐T cells. In vivo, mice treated with EphB4 CAR‐T cells displayed a significantly lower tumor burden than those treated with either CD19 CAR‐T cells or phosphate‐buffered saline. Additionally, mice treated with EphB4 CAR‐T cells survived significantly longer than those in the other groups. In conclusion, ligand‐based EphB4 CAR‐T cells are bispecific, targeting both EphB4 and EphA2. Furthermore, these cells exert significant antitumor effects against lung adenocarcinoma.


  • Chemotherapy-associated lineage shift of T/myeloid mixed-phenotype acute leukemia into AML-MRC: a case report

    by Yohei Gouzu, Yuichiro Ide, Shohei Shigeto, Takamasa Saito, Yu Furui, Eri Okura, Kenichi Sakamoto, Koichi Hirabayashi, Yozo Nakazawa, Shoji Saito

  • Open Access

    Efficacy of Noninvasive Neurally Adjusted Ventilatory Assist (NIV‐NAVA) for Neonates With Transient Tachypnea of the Newborn: A Retrospective Analysis

    by Takamasa Saito, Yuta Maruyama, Yukihide Miyosawa, Koichi Hirabayashi, Yozo Nakazawa

    Background: Noninvasive neurally adjusted ventilatory assist (NIV‐NAVA) provides synchronized respiratory support based on diaphragmatic electrical activity and has shown efficacy in preterm neonates. However, its efficacy in late preterm and term neonates with transient tachypnea of the newborn (TTN) remains unclear. Methods: We retrospectively analyzed 183 neonates (≥ 34 weeks' gestation) with TTN between 2016 and 2024 who received initial respiratory support with either NIV‐NAVA ( n = 68) or sigh positive airway pressure (SiPAP, n = 115). After propensity score matching (PSM), we compared primary outcomes of intubation and treatment failure, the latter defined as a device switch within 6 h. Secondary outcomes included the duration of oxygen therapy. Results: After PSM, 84 neonates (42 per group) were included. The intubation rates did not differ significantly between the SiPAP and NIV‐NAVA groups (21.4% vs. 7.1%; p = 0.116). However, treatment failure was significantly lower in the NIV‐NAVA group (31.0% vs. 7.1%; p = 0.011) and a shorter duration of oxygen therapy (median, 18 vs. 6 h; p = 0.031). No significant adverse events were observed in either group. Conclusion: NIV‐NAVA appears to be an effective alternative to SiPAP for managing TTN in late preterm and term neonates. It demonstrated a comparable intubation rate while offering the significant benefits of reducing treatment failure and the duration of oxygen therapy. Further large‐scale, prospective studies are warranted to confirm these important findings.


  • Open Access

    Development of a Serious Game to Simulate Neonatal Intensive Care Unit Experiences: Collaborative Quasi-Experimental Study

    by Yukihide Miyosawa, Koichi Hirabayashi, Kodai Yamada, Fumiya Kobayashi, Nanami Ogihara, Noa Takeda, Eri Okamura, Shogo Matsumura

    Background: Opportunities for neonatal intensive care unit (NICU) training are limited for medical and nursing students due to patient safety concerns and the complexities of neonatal care. In addition, the COVID-19 pandemic significantly disrupted clinical training opportunities, further underscoring the need for alternative educational tools that can provide immersive and practical learning experiences. Serious games have garnered attention as potential tools for medical education; however, few are designed to simulate the complete NICU environment and its unique challenges. Objective: To address the educational gaps in neonatal care training, we aimed to develop and evaluate a serious game that provides a comprehensive NICU simulation experience for students and the general public. Methods: The game was developed over 14 months by a collaborative team that included a neonatologist, 4 medical students, and 1 art student, with a total cost of US $10,000. Initially created in TyranoBuilder (STRIKEWORKS), the game was later redeveloped in Unity with Naninovel to support multilingual functionality. Structured as a 6-chapter visual novel, the game follows a high school student observing the NICU during a hospital internship. Scenario-based decision-making and interactive dialogues guide the player through both the clinical and emotional aspects of neonatal care. After completing the game, players were invited to participate in an optional web-based survey that assessed demographic information, gameplay quality, and educational value using Likert scales. Descriptive and inferential statistics were used for data analysis. Results: The game, titled First Steps in the NICU, was released for iOS, Android, and Steam. As of May 2025, it has been downloaded 2799 times (2260 on iOS and 539 on Android). A total of 160 survey responses were collected, with 46.3% of respondents identifying as health care professionals or students. The majority of participants were female (114/160, 71.3%) and aged 20-29 years (59/160, 36.9%). Mean scores for length, difficulty, and gameplay were 3.05 (SD 0.62), 2.49 (SD 0.76), and 3.65 (SD 0.77), respectively, indicating a well-balanced design. The educational usefulness of the game received high ratings: empathy with the story (4.24), usefulness for knowledge acquisition (4.16), and effectiveness of serious games as a learning tool (4.37). No significant differences in evaluations were found between health care professionals and students and the general public, suggesting broad accessibility and appeal. Conclusions: We developed a low-cost serious game that simulates NICU experiences through collaboration between a neonatologist and students. The game received positive feedback and demonstrated educational value for a diverse audience. Positioned as formative research, this study highlights the potential of serious games to supplement neonatal care education. Future updates will incorporate user feedback, leading to improvements in gameplay and expanded content.


  • Open Access

    Ligand‐Based CAR‐T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies

    by Manaka Shinagawa, Koichi Hirabayashi, Marina Fujioka, Kyosuke Kamijo, Natsuki Uchiyama, Yusuke Yokokawa, Yasuhiro Tanaka, Motoki Ono, Thanyavi Chinsuwan, Ryoichi Asaka, et al.

    Epidermal growth factor receptor (EGFR) has been reported to be overexpressed in gynecologic malignancies. However, the clinical efficacy of existing molecular EGFR‐targeted therapies against gynecologic malignancies has not been demonstrated. In this study, we investigated the antitumor effects of ligand‐based EGFR chimeric antigen receptor (CAR)‐T cells on gynecologic malignancies. First, we evaluated EGFR expression in patient samples using immunohistochemistry. EGFR positivity was observed in 41%, 82%, and 79% of ovarian, endometrial, and cervical cancer in patient samples, respectively. Second, we generated ligand‐based EGFR CAR‐T cells via piggyBac‐mediated gene transfer. EGFR CAR‐T cells were successfully generated with high CAR positivity and a high proportion of naïve/stem cell memory‐like T cells. Finally, we investigated the antitumor effects of EGFR CAR‐T cells on gynecologic malignancies. EGFR CAR‐T cells were co‐cultured with six EGFR‐positive gynecologic cancer cell lines. The growth of all six gynecologic cancer cell lines was significantly suppressed by EGFR CAR‐T cells compared to mock T cells. In in vivo studies, tumor‐bearing mice implanted with gynecologic cancer cell lines in their intraperitoneal cavity were administered EGFR CAR‐T cells, CD19 CAR‐T cells, or PBS intraperitoneally. Mice treated with EGFR CAR‐T cells displayed a significantly decreased tumor burden compared to those treated with either CD19 CAR‐T cells or PBS. Additionally, mice treated with EGFR CAR‐T cells had a significantly longer survival than the other groups. In summary, ligand‐based EGFR CAR‐T cells may be a promising therapy for various gynecologic malignancies.


  • Open Access

    Development of a Serious Game to Simulate Neonatal Intensive Care Unit Experiences: Collaborative Quasi-Experimental Study (Preprint)

    by Yukihide Miyosawa, Koichi Hirabayashi, Kodai Yamada, Fumiya Kobayashi, Nanami Ogihara, Noa Takeda, Eri Okamura, Shogo Matsumura

    BACKGROUND Opportunities for neonatal intensive care unit (NICU) training are limited for medical and nursing students due to patient safety concerns and the complexities of neonatal care. In addition, the COVID-19 pandemic significantly disrupted clinical training opportunities, further underscoring the need for alternative educational tools that can provide immersive and practical learning experiences. Serious games have garnered attention as potential tools for medical education; however, few are designed to simulate the complete NICU environment and its unique challenges. OBJECTIVE To address the educational gaps in neonatal care training, we aimed to develop and evaluate a serious game that provides a comprehensive NICU simulation experience for students and the general public. METHODS The game was developed over 14 months by a collaborative team that included a neonatologist, 4 medical students, and 1 art student, with a total cost of US $10,000. Initially created in TyranoBuilder (STRIKEWORKS), the game was later redeveloped in Unity with Naninovel to support multilingual functionality. Structured as a 6-chapter visual novel, the game follows a high school student observing the NICU during a hospital internship. Scenario-based decision-making and interactive dialogues guide the player through both the clinical and emotional aspects of neonatal care. After completing the game, players were invited to participate in an optional web-based survey that assessed demographic information, gameplay quality, and educational value using Likert scales. Descriptive and inferential statistics were used for data analysis. RESULTS The game, titled First Steps in the NICU, was released for iOS, Android, and Steam. As of May 2025, it has been downloaded 2799 times (2260 on iOS and 539 on Android). A total of 160 survey responses were collected, with 46.3% of respondents identifying as health care professionals or students. The majority of participants were female (114/160, 71.3%) and aged 20-29 years (59/160, 36.9%). Mean scores for length, difficulty, and gameplay were 3.05 (SD 0.62), 2.49 (SD 0.76), and 3.65 (SD 0.77), respectively, indicating a well-balanced design. The educational usefulness of the game received high ratings: empathy with the story (4.24), usefulness for knowledge acquisition (4.16), and effectiveness of serious games as a learning tool (4.37). No significant differences in evaluations were found between health care professionals and students and the general public, suggesting broad accessibility and appeal. CONCLUSIONS We developed a low-cost serious game that simulates NICU experiences through collaboration between a neonatologist and students. The game received positive feedback and demonstrated educational value for a diverse audience. Positioned as formative research, this study highlights the potential of serious games to supplement neonatal care education. Future updates will incorporate user feedback, leading to improvements in gameplay and expanded content.

  • Epstein–Barr virus‐associated lymphoproliferative disease in a patient with Shimke immuno‐osseous dysplasia

    by Hiroki Kohmo, Kenichi Sakamoto, Eri Okura, Tsubasa Murase, Koichi Hirabayashi, Shoji Saito, Yozo Nakazawa

  • Ruxolitinib for preventing relapse of Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis

    by Eri Okura, Kenichi Sakamoto, Yuta Maruyama, Koichi Hirabayashi, Shoji Saito, Ryu Yanagisawa, Yozo Nakazawa


  • Open Access

    Long‐Term Outcomes of Reduced‐Toxicity Conditioning Using 8‐Gray Total Body Irradiation, Fludarabine, and Cyclophosphamide in Children, Adolescents, and Young Adults With Hematological Malignancies

    by Hirokazu Morokawa, Koichi Hirabayashi, Yu Furui, Eri Okura, Shoji Saito, Yozo Nakazawa

    Recent studies have indicated that total body irradiation (TBI)‐based reduced‐toxicity conditioning (RTC) may be a potential treatment modality, especially in adults with leukemia. However, its efficacy and safety in children with hematological malignancies remain unclear. To investigate the long‐term outcomes and safety of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) using an 8‐Gray (Gy) TBI/fludarabine (FLU)/cyclophosphamide (CY) RTC in children with hematological malignancies. We included 66 consecutive patients with leukemia, lymphoma, or myelodysplastic syndrome in this retrospective cohort study. Participants were < 25 years old and received an 8‐Gy TBI/FLU/CY RTC regimen followed by the first allo‐HSCT at Shinshu University Hospital between March 2004 and March 2021. The 5‐year overall and relapse‐free survival probabilities were 88.2% and 76.5%, respectively, in the lymphoid malignancy group. The myeloid malignancy group had probabilities of 72.4% and 58.6%, respectively. The 5‐year cumulative incidences of relapse and non‐relapse mortality were 20.6% and 2.9%, respectively, in the lymphoid malignancy group. These incidences were 37.9% and 3.4%, respectively, in the myeloid malignancy group. All patients had engraftment without early relapse and none developed grade 5 regimen‐related toxicity within 28 days after allo‐HSCT. Nonetheless, two patients had congenital abnormalities caused by chromosomal aberrations and died without relapse. 8‐Gy TBI/FLU/CY RTC was safe in children with hematological malignancies, regardless of the donor source. However, safety concerns were noted in cases of chromosomal aberration‐induced congenital abnormalities. Additionally, patients in the lymphoid and myeloid malignancy groups had favorable prognoses.


  • Successful ibrutinib treatment for pulmonary involvement in a post‐transplant patient with inherited bone marrow failure syndrome and very short telomeres

    by Yu Furui, Shoji Saito, Yuta Maruyama, Eri Okura, Koichi Hirabayashi, Miyuki Tanaka, Yozo Nakazawa